Early Benefit Assessment of Tislelizumab NSCLC ...

By João L. Carapinha

April 1, 2025

The German Federal Joint Committee (G-BA) has initiated an early benefit assessment for tislelizumab NSCLC treatment. It's used as monotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) following plat...
Neoadjuvant Chemoimmunotherapy HNSCC in Advanced HPV-Negative Patients
Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?
Advancing Heart Transplantation: The Role of the Lumped Parameter Model
Liquid Biopsy Colorectal Cancer Screening Expands in Abu Dhabi
Colorectal Cancer in Young Women: Rising Risks and Urgent Need for Awareness
Survival Benefits of Immune Checkpoint Inhibitors in Metastatic Colorectal Ca...
FDA Warning Aspen Pharmacare: Evaluating Compliance Violations and Their Impact
Global Partnerships SCD in Africa
Molecular Insights into Angiogenesis in Colorectal Cancer
Enhancing Colorectal Cancer Screening Through Mail and Navigation Strategies
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
Deadline Boosts Colorectal Cancer Screening Uptake in TEMPO Trial